Status:
UNKNOWN
Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis
Lead Sponsor:
Bayside Health
Collaborating Sponsors:
National Health and Medical Research Council, Australia
Monash University
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
Adult cystic fibrosis (CF) patients admitted with an acute infection complicated by acid-base disturbance and decreased ventilation will be studied. They will receive salt replacement to correct the ...
Detailed Description
Background: Hypochloremic hypovolemic metabolic alkalosis contributes to hypercapnia in acute exacerbations of cystic fibrosis. Treatment of the metabolic alkalosis with volume and sodium chloride (Na...
Eligibility Criteria
Inclusion
- Adult cystic fibrosis patient
- Admission with acute exacerbation (criteria- fall in FEV1 \> 10% from best in last 12/12, change in sputum volume and colour, new pulmonary infiltrate)
- PaCO2 \> 45 mmHg on admission
- Primary metabolic alkalosis (acid-base diagram of Stinebaugh and Austin)
- Serum chloride (Cl) ≤ 98 mmol/L
- Serum albumin (alb) ≤ 25 mmol/L
Exclusion
- Concurrent diuretic therapy Concurrent glucocorticoid therapy
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00163852
Start Date
February 1 2004
End Date
February 1 2006
Last Update
September 14 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Alfred
Melbourne, Victoria, Australia, 3181